Abstract

Objective. To study the effect of infliximab (INF) on serum levels of RANKL and osteoprotegerin (OPG), as well as on structural and functional properties of the vascular wall in patients with rheumatoid arthritis (RA). Material and Methods. A total of 79 RA patients who corresponded to the classification criteria ACR (1987) or ACR/EULAR (2010) and were seronegative for IgM rheumatoid factor (RF) were examined. The mean age of patients was 43.6±8.5 years. The serum levels of OPG and RANKL were determined by ELISA (Biomedica, Austria); the common carotid arteries (CCAs) were visualized using an Acuson X/10 ultrasonic complex equipped with a 7 MHz linear sensor in the β-mode prior to therapy and after 12-month therapy with INF. Results and Discussion. An increased OPG level was observed mostly in patients with RA duration up to 1 year; an increase in RANKL level was pronounced stronger in patients with PA duration over 2 years. The disturbance of structural and functional properties of the arterial bloodstream was revealed, manifesting itself as an increase in the intimamedia complex thickness, diameter and rigidity index of CCA that were stronger pronounced in patients with late onset RA. A correlation analysis showed the presence of reliable relationship between the RANKL and OPG levels and CCA remodeling parameters. INF therapy showed high clinical effectiveness and correction effect on the RANKL/OPG system. In addition, it was accompanied by a reduction of signs of CCA remodeling, which was stronger pronounced in patients with early RA. Conclusion. The results prove the reasonability of using INF at early stages of RA in order to optimize the therapy and achieve more efficient control of cardiovascular complications.

Highlights

  • Целью исследования явилось изучение влияния инфликсимаба (ИНФ) на уровень в сыворотке крови RANKL и остеопротегерина (ОПГ) и структурно-функциональные свойства сосудистой стенки у больных ревматоидным артритом (РА)

  • INF therapy showed high clinical effectiveness and correction effect on the RANKL/OPG system. It was accompanied by a reduction of signs of common carotid arteries (CCAs) remodeling, which was stronger pronounced in patients with early rheumatoid arthritis (RA)

  • The results prove the reasonability of using INF at early stages of RA in order to optimize the therapy and achieve more efficient control of cardiovascular complications

Read more

Summary

Оригинальные исследования

Влияние инфликсимаба на параметры ремоделирования артериального русла, уровень RANKL и остеопротегерина у больных ревматоидным артритом. Целью исследования явилось изучение влияния инфликсимаба (ИНФ) на уровень в сыворотке крови RANKL и остеопротегерина (ОПГ) и структурно-функциональные свойства сосудистой стенки у больных ревматоидным артритом (РА). Отмечалось повышение уровня ОПГ, преимущественно у пациентов с длительностью РА до 1 года, и RANKL, более выраженное при длительности РА >2 лет. Выявлены нарушения структурно-функциональных свойств артериального русла, проявляющиеся увеличением толщины комплекса интима–медиа, диаметра и индекса жесткости ОСА, более выраженные при позднем РА. Терапия ИНФ наряду с высокой клинической эффективностью и корригирующим влиянием на систему RANKL/ОПГ сопровождалась уменьшением признаков ремоделирования ОСА, более выраженным при раннем РА. Влияние инфликсимаба на параметры ремоделирования артериального русла, уровень RANKL и остеопротегерина у больных ревматоидным артриром.

Objective
No исследования
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.